Research Analysts Set Expectations for ZVRA FY2024 Earnings

Research analysts at Roth Capital have revised down their projected earnings for Zevra Therapeutics in the year 2024 in a report provided to clients and investors on Tuesday the 12th of November this year. J.Aschoff from Roth Capital now expects the company to report earnings per share of ($ ̶9̶5̶2̶C̶$ ) US$ownload; Reuters StreeetEvents transcriptTheStreetTranscript"]elve from their estimate of ($ 960C$). The overall consensus forecast, for Zevra Therapeutics’ full year earnings stands at ($163.) per share. According to Roth Capitals predictions for Zevra Therapeutics performance in the coming years; they estimate the fourth quarter of 2024 to have earnings per share of ($ 038) the first quarter of 2025 with an EPS of ($030) the second quarter of 2025 at ($012) the third quarter of 2025 at ($004) full year earnings for 2025 at ($031). For year 2026 they predict earnings to be $067 EPS and projecting even higher for fiscal year 2027 with $141 EPS followed by an estimate of $185 EPS, for fiscal year 2028.

Several analysts in the stock market have recently released reports regarding Zevra Therapeutics stock price outlooks and recommendations for investors consideration. Canaccord Genuity Group revised their target price for Zevra Therapeutics shares from $25 to $23 while maintaining a "buy" recommendation, in a report published on Thursday. HC Wainwright also reiterated their "buy" recommendation. Set a price target of $20 for Zevra Therapeutics shares in a report dated Monday September 30th. The target price for Zevra Therapeutics shares was increased by Roth Mkm from$19 to$21. They rated the stock as a "buy." This update was provided in their research note on Tuesday the 24th of September.JMP Securities began covering Zevra Therapeutics on the day as they gave it an "outperform'' rating along with a target price of$17, per share. Maxim Group recently increased their price target for Zevra Therapeutics shares from $18 to $25. Recommended buying the stock in a research report on Tuesday the 24th of September. Of the seven research analysts who evaluated the stocks performance far; one strongly recommends buying it and all others have given it a positive rating. As per MarketBeat.coms data analysis; the company holds a Buy" rating, with an average target price of $21.

Check out the recent study findings about Zevra Therapeutics, in our new research report.

On the opening day of trading for Zebra Pharmaceuticals (ticker symbol; ZVRA) the stock started at $8 in the morning on a bright and sunny day last week! Looking back over the year or so this companys stock price has been steadily climbing up from around $5 to its current value of about $10 per share. Quite an impressive journey indeed! When it comes to health indicators like liquidity and debt levels at Zebra Pharmaceuticals Inc. they seem to be in a fairly stable position with healthy ratios across the board; quick ratio and current ratio both standing strong at 2 while debt to equity ratio is not too high, at 1.

Zevra Therapeutics is a company based in the United States dedicated to uncovering and creating unique prodrugs to address critical health issues in the country.The firm focuses on advancing its product line utilizing the Ligand Activated Therapy platform.KP1077 represents their flagship product, in development; it includes KP1077IH undergoing Phase 2 clinical trials for combatting idiopathic hypersomnia and KP1077N being tested in Phase 1/2 clinical trials for managing narcolepsy.

This breaking news update was created using cutting edge narrative science technology and financial information sourced from MarketBeat aiming to deliver precise reporting to readers fingertips promptly. Before its release this article underwent review by the editorial team, at MarketBeat. For any inquiries or feedback regarding this piece kindly direct them to contact(at)marketbeat(dot)com.

Before diving into Zevra Therapeutics offerings and services, in detail

MarketBeat monitors the recommendations of leading research analysts and the stocks they suggest to their clients daily highlighting five stocks favored by analysts as attractive buys before they gain wider market attention. Notably Zevra Therapeutics did not make the cut.

Zevra Therapeutics is currently rated as a "Buy' by analysts; however rated analysts recommend considering these five stocks, for better investment opportunities.